The FDA proposed new steps intended to cut the time needed to start first-in-human trials, using a budget-driven regulatory pathway approach. The plan would introduce an optional, risk-based expedited Investigational New Drug route for some programs where existing preclinical data could support clinical initiation without additional animal studies. In industry-facing terms, the proposal aims to lower early development costs and streamline entry to U.S. Phase 1 trials—an effort positioned against increasing overseas activity in early clinical development. The FDA also discussed plans to use the proposal to create a more predictable, faster path for eligible drug candidates. Separate but related reporting notes that the FDA is also exploring broader domestic manufacturing and early-trial incentives as part of the same regulatory overhaul theme. Together, the proposals signal a push to reduce friction for sponsors earlier in the development cycle.